Proactive Investors - Run By Investors For Investors

Botanix Pharmaceuticals treats first patient in phase 1b psoriasis study

Uniquely designed patient study which allows the comparison of multiple drugs on the same patient at the same time.
BTX 1308 is Botanix’s third product to commence a patient study in the last 12 months

Botanix Pharmaceuticals Ltd (ASX:BOT) has treated the first patient in its phase 1b BTX 1308 psoriasis patient study.

The study is testing a new formulation of synthetic cannabidiol combined with the company’s novel Permetrex skin delivery technology.

The phase 1b patient study is being conducted in collaboration with BioSkin GmbH, a German clinical contract research organisation and an Australian dermatology clinic.

Bioskin is internationally recognised for their experience with the psoriasis plaque test which is clinically validated and utilised by a number of leading dermatology companies.

The study is designed to assess the safety and efficacy of BTX 1308 on psoriasis plaques or lesions, with the ability to compare multiple formulations and test products at the same time, and on the same patient.

Botanix is advancing multiple clinical programs with near-term milestones

Botanix founder and executive director Matt Callahan said: “We are pleased to have enrolled and treated our first patient in the BTX 1308 psoriasis study.

“The unique design of this patient study which allows us to compare multiple drugs in the same patient at the same time, means that the treatment duration can be shortened, while the quality of data can also be enhanced.

“BTX 1308 is our third product to commence a patient study in the last 12 months, which demonstrates our ability to rapidly add new indications to the pipeline, as we can leverage the studies already successfully completed with synthetic cannabidiol in acne and atopic dermatitis.”

View full BOT profile View Profile

Botanix Pharmaceuticals Ltd Timeline

Related Articles

A doctor's stethoscope and a marijuana plant
February 23 2019
With top-line data from the CONNECT-FX trial on the way, investors are eying the opportunity defined by marijuana-adjacent companies like Zynerba Pharmaceuticals
scientist in lab
December 18 2018
VAL401 is ValiRx’s most advanced compound, with earlier trial results suggesting it can improve quality of life and chances of survival of lung cancer patients
lung in x-ray
February 25 2019
The company has been developing a treatment for chronic lung disease in-house and has partnered with an Australian group to develop a drug for rare liver and lung complaints

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use